Effect of actinomycin-D and cycloheximide on bFGF- and serum-induced TFPI expression. Quiescent PASMC monolayers were pretreated with actinomycin-D (5 μg/mL) or cycloheximide (10 μg/mL) for 1 hour and then treated with serum (10% vol/vol) or bFGF/heparin (10 ng/15 U/mL) for 24 hours. Conditioned media was assayed for TFPI activity (A) or analyzed for TFPI antigen by Western blot analysis (B). Control (in panel A) and none (in panel B) represent serum or bFGF/heparin treatments in the absence of inhibitor.